Table 2.

Investigational therapies in pediatric HGGs

Therapy	Mode of Action
Cilengitide	αvβ3 and αvβ5 integrin inhibitor
Enzastaurin (LY317615)	Anti-angiogenic; protein kinase C inhibitor
MK-2206	Akt inhibitor
IL13-PE38QQR	Cytotoxic to Interleukin-13–expressing cells
Nimotuzumab	EGFR inhibitor
Cetuximab	EGFR inhibitor
MK-0752	Gamma secretase inhibitor
RO4929097	Gamma secretase inhibitor
Valproic acid	Histone deacetylase inhibitor
Vorinostat	Histone deacetylase inhibitor
LDE225	Inhibitor of the Smoothened G-protein–coupled receptor
ABT-888	Poly(ADP-ribose) polymerase inhibitor
Dendritic cells	Vaccine
Bevacizumab	VEGF inhibitor
Cediranib (AZD2171)	VEGF receptor tyrosine kinase inhibitor